Xilio Therapeutics Inc (XLO) concluded trading on Thursday at a closing price of $0.94, with 3.72 million shares of worth about $3.5 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 3.26% during that period and on December 19, 2024 the price saw a gain of about 8.25%. Currently the company’s common shares owned by public are about 43.96M shares, out of which, 20.53M shares are available for trading.
Stock saw a price change of -8.93% in past 5 days and over the past one month there was a price change of -8.04%. Year-to-date (YTD), XLO shares are showing a performance of 70.55% which increased to 56.07% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.49 but also hit the highest price of $1.93 during that period. The average intraday trading volume for Xilio Therapeutics Inc shares is 237.58K. The stock is currently trading -5.75% below its 20-day simple moving average (SMA20), while that difference is down -6.38% for SMA50 and it goes to -3.13% lower than SMA200.
Xilio Therapeutics Inc (NASDAQ: XLO) currently have 43.96M outstanding shares and institutions hold larger chunk of about 16.09% of that.
The stock has a current market capitalization of $41.23M and its 3Y-monthly beta is at -0.19. It has posted earnings per share of -$1.72 in the same period. It has Quick Ratio of 1.67 while making debt-to-equity ratio of 0.40. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XLO, volatility over the week remained 13.62% while standing at 10.10% over the month.
Stock’s fiscal year EPS is expected to rise by 58.99% while it is estimated to increase by 55.56% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Chardan Capital Markets on December 21, 2022 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by H.C. Wainwright stated Xilio Therapeutics Inc (XLO) stock as a Buy in their note to investors on January 10, 2022, suggesting a price target of $36 for the stock. On November 16, 2021, Raymond James Initiated their recommendations, while on November 16, 2021, Morgan Stanley Initiated their ratings for the stock with a price target of $32. Stock get a Buy rating from Guggenheim on November 16, 2021.
